JG
SGMO

Joel Greenblatt’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Joel Greenblatt’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-26,695
Closed -$400K – 1048
2017
Q3 		$400K Buy
+26,695
New +$295K 0.01% 743
2015
Q3 		– Sell
-30,334
Closed -$336K – 1027
2015
Q2 		$336K Buy
+30,334
New +$391K ﹤0.01% 800
2015
Q1 		– Sell
-17,441
Closed -$265K – 1014
2014
Q4 		$265K Buy
+17,441
New +$212K ﹤0.01% 857

Other funds holding SGMO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CCS
Crosspoint Capital Strategies Orinda, California $50.4M AUM 15.37% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Joel Greenblatt's SGMO Position: Q4 2017 in Review

Joel Greenblatt sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q4 2017, closing a stake of 26,695 shares — an estimated $400K sold.

Joel Greenblatt first reported a position in SGMO in Q4 2014 and held it in 3 quarters. The position peaked at $400K in Q3 2017. 170 funds tracked by Wall St. Rank hold SGMO as of Q4 2017.

  • Joel Greenblatt reported no remaining SANGAMO THERAPEUTICS INC position as of Q4 2017 after selling out during the quarter.
  • Joel Greenblatt sold 26,695 SANGAMO THERAPEUTICS INC shares in Q4 2017, an estimated $400K.
  • Joel Greenblatt first reported a position in SANGAMO THERAPEUTICS INC in Q4 2014 and held it in 3 quarters.
  • Joel Greenblatt's SANGAMO THERAPEUTICS INC position peaked at $400K in Q3 2017.
  • 170 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q4 2017.

Based on Gotham Asset Management's 13F filing for Q4 2017, filed 14 Feb 2018.